These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15872296)

  • 1. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.
    Zöllner B; Sterneck M; Wursthorn K; Petersen J; Schröter M; Laufs R; Feucht HH
    J Clin Microbiol; 2005 May; 43(5):2503-5. PubMed ID: 15872296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.
    Pas SD; de Man RA; Fries E; Osterhaus AD; Niesters HG
    J Clin Virol; 2002 Jul; 25(1):63-71. PubMed ID: 12126723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon and lamivudine for hepatitis B.
    Assy NN; Hussein O
    N Engl J Med; 2004 Dec; 351(27):2879; author reply 2879. PubMed ID: 15625344
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
    Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
    J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
    Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
    J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
    Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
    J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
    Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
    J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No benefit to continue lamivudine therapy after emergence of YMDD mutations.
    Liaw YF; Chien RN; Yeh CT
    Antivir Ther; 2004 Apr; 9(2):257-62. PubMed ID: 15134188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
    Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
    J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
    Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E
    J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
    Hatakeyama T; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Kawakami Y; Fujimoto Y; Ochi H; Abe H; Maekawa T; Kawakami H; Yatsuji H; Aisaka Y; Kohno H; Aimitsu S; Chayama K
    Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.